Literature DB >> 11289118

Association between DNA repair-deficiency and high level of p53 mutations in melanoma of Xeroderma pigmentosum.

A Spatz1, G Giglia-Mari, S Benhamou, A Sarasin.   

Abstract

Xeroderma pigmentosum (XP) is an inheritable disease characterized by sun-sensitivity and a high frequency of skin cancers including melanoma. We have analyzed two different groups of XP: the XP complementation group C (XP-C), deficient in global nucleotide excision repair but proficient in transcription-coupled repair and associated with a very early onset of skin cancers; and the XP variant (XPV), deficient in the bypass of DNA photoproducts. To get new insights into the biology of melanoma in XP patients, we studied 20 melanomas from four XP-C and two XPV patients in terms of pathology, immunohistochemistry of p53, mutations in exons 4-9 of the p53 gene, and polymorphisms of the p53 gene at codon 72. All statistical tests were two-sided. The majority of the XP melanomas were of the lentigo maligna melanoma (LMM) type, as found in the elderly. p53 point mutations were found in 60% of XP-C melanomas and in only 10% of XPV melanomas, this latter frequency being similar to what has been reported in the general population. Mutations show the specific UV-signature because the majority were CC to tandem and C to T transitions located at the bipyrimidine sites known to be hotspots of UV-induced DNA lesions. All DNA lesions giving rise to mutations in XP-C melanomas were located on the nontranscribed strand of the p53 gene, demonstrating that these patients' cells were able to carry out preferential repair in vivo. The LMMs found in XP-C are associated with an accumulation of unrepaired DNA lesions and may represent a good model for the LMM induction in the elderly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289118

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Diagnosis of Xeroderma Pigmentosum and Related DNA Repair-Deficient Cutaneous Diseases.

Authors:  James E Cleaver
Journal:  Curr Med Lit Dermatol       Date:  2008

2.  Revisiting the photochemistry of solar UVA in human skin.

Authors:  David Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-05       Impact factor: 11.205

3.  The DNA damage-binding protein XPC is a frequent target for inactivation in squamous cell carcinomas.

Authors:  Sebastien de Feraudy; Katie Ridd; Lauren M Richards; Pui-Yan Kwok; Ingrid Revet; Dennis Oh; Luzviminda Feeney; James E Cleaver
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

Review 4.  cAMP-mediated regulation of melanocyte genomic instability: A melanoma-preventive strategy.

Authors:  Nathaniel C Holcomb; Robert-Marlo Bautista; Stuart G Jarrett; Katharine M Carter; Madeline Krentz Gober; John A D'Orazio
Journal:  Adv Protein Chem Struct Biol       Date:  2018-12-05       Impact factor: 3.507

Review 5.  Childhood exposure to ultraviolet radiation and harmful skin effects: epidemiological evidence.

Authors:  Adèle C Green; Sarah C Wallingford; Penelope McBride
Journal:  Prog Biophys Mol Biol       Date:  2011-09-03       Impact factor: 3.667

6.  Classifying melanocytic tumors based on DNA copy number changes.

Authors:  Boris C Bastian; Adam B Olshen; Philip E LeBoit; Daniel Pinkel
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

7.  Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma.

Authors:  Brozyna Anna; Zbytek Blazej; Granese Jacqueline; Carlson J Andrew; Ross Jeffrey; Slominski Andrzej
Journal:  Expert Rev Dermatol       Date:  2007

Review 8.  Sun exposure, sunbeds and sunscreens and melanoma. What are the controversies?

Authors:  Veronique Bataille
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

9.  Increased risk of cutaneous melanoma associated with p53 Arg72Pro polymorphism.

Authors:  Peiliang Geng; Yunmei Liao; Zhihua Ruan; Houjie Liang
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.